News Releases

January 2021

January 25, 2021 1/25/2021 Takeda Named Global Top Employer for Fourth Consecutive Year

January 22, 2021 1/22/2021 Manufacturing and Marketing Approval Received in Japan for ALUNBRIG® in the Treatment of ALK Fusion Gene-positive Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer

January 19, 2021 1/19/2021 Takeda to Hold Investor Call on January 29 During World Conference on Lung Cancer

January 11, 2021 1/11/2021 Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50 percent by FY2030 at the 39th Annual JP Morgan Healthcare Conference

January 11, 2021 1/11/2021 Takeda to Present at The 39th Annual J.P. Morgan Healthcare Conference

January 5, 2021 1/5/2021 Takeda Completes Sale of Select Non-Core Assets to Cheplapharm

December 2020

December 21, 2020 12/21/2020 Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD

December 18, 2020 12/18/2020 U.S. FDA Approves Supplemental New Drug Application for Takeda’s ICLUSIG® (ponatinib) for Adult Patients with Resistant or Intolerant Chronic-Phase CML

December 15, 2020 12/15/2020 U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis